Abstract
The 2014 Santa Fe Bone Symposium provided a setting for the presentation and discussion of the clinical relevance of recent advances in the fields of osteoporosis and metabolic bone disease. The format included oral presentations of abstracts by endocrinology fellows, plenary lectures, panel discussions and breakout sessions, with ample opportunities for informal discussions before and after scheduled events. Topics addressed in these proceedings included a review of the important scientific publications in the past year, fracture prevention in patients with dysmobility and immobility, fracture liaison services for secondary fracture prevention, management of pre-menopausal osteoporosis, the role of bone microarchitecture in determining bone strength, measurement of microarchitecture in clinical practice and methods to improve the quality of bone density testing. This is a report of the proceedings of the 2014 Santa Fe Bone Symposium.
Declaration of interest
John P. Bilezikian, MD, Consultant in Amgen, Lilly, Merck, NPS, Bristol Meyers Squibb, Johnson & Johnson and Radius. Neil Binkley, MD, Consultant/Advisory Board in Amgen, Lilly and Merck. Research Support by Amgen, Lilly, Merck, Opko. Didier Hans, MD, Grant/Research Support by Amgen, Eli Lilly, Radius Pharma. Co-owner of the TBS patent and has corresponding ownership shares/position at Medimaps group. Diane Krueger, BS, CBDT, No financial relationships to disclose. E. Michael Lewiecki, MD, Grant/Research Support by Amgen, Eli Lilly and Merck. Scientific Advisory Board: Amgen, Eli Lilly, Merck, NPS, Radius Health and AgNovos. Paul D. Miller, MD, Scientific Advisory Board: Amgen, Lilly, Radius Research and Merck. Grant/Research Support by Amgen, Lilly, Merck, Novo Nordisk, Radius Health, Takeda. Mary K. Oates, MD, Honorarium/Speaker in Shionogi, Lilly. Honorarium/Advisory Committee: Tarsa. Research Support by Amgen. Elizabeth Shane, MD, Honorarium/Speakerin Amgen. Research Grant by Lilly.